RE:Importance of good clinical results on display at BCT Yes newday it will all come down to the Clinic.
Dispiriting (perhaps deliberately so for the MMs) to see the stock run down again and again from such modest levels and at such low volumes but we won’t see support without emphatic Clinical evidence.
For some of us this may come with the next Quarterly and a more certain CR status for the 5 survivors from among the 6 patients that for many of us were the main focus last time.
If these results have gone as we hope they should improve perception and from then on Rutherrin should start to come into play, if only marginally at first with the announcement of toxicity studies.
By the end of the Year the reality of what is proposed for 2022 - being the economic elegant humane and effective treatment of some of the deadliest cancers in humans - may start to become more widely appreciated.